190:@0.017061:0.038809:0.056572:0.038809:0.056572:0.019212:0.017061:0.019212:0.013170:0.013170:0.013170
HANDBOOK OF ONCOLOGY:@0.084848:0.970015:0.320957:0.970015:0.320957:0.956010:0.084848:0.956010:0.011682:0.012657:0.012657:0.012726:0.009818:0.014864:0.014864:0.010109:0.004738:0.014864:0.008296:0.004738:0.014864:0.012657:0.013906:0.014864:0.007902:0.014864:0.014915:0.010126
concurrent platinum-based :@0.115151:0.079499:0.376794:0.079499:0.376794:0.063743:0.115151:0.063743:0.012450:0.012604:0.011738:0.012450:0.011699:0.005792:0.005700:0.012508:0.011738:0.006523:0.005330:0.013123:0.003848:0.013143:0.006523:0.003848:0.011738:0.011699:0.018049:0.006388:0.013123:0.013143:0.007466:0.012508:0.013181:0.005330
chemotherapy and radiation therapy:@0.115151:0.095162:0.466652:0.095162:0.466652:0.079406:0.115151:0.079406:0.012450:0.011738:0.012508:0.018049:0.012604:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.005330:0.013143:0.011738:0.013181:0.005330:0.005792:0.013143:0.013181:0.003848:0.013143:0.006523:0.003848:0.012604:0.011738:0.005330:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314
Ipilimumab:@0.084848:0.125923:0.201586:0.125923:0.201586:0.107902:0.084848:0.107902:0.005987:0.014111:0.005131:0.005131:0.005131:0.020098:0.012828:0.020098:0.014111:0.014111
CTLA-4 is a negative regulator of T-cell ac-:@0.084848:0.144201:0.475771:0.144201:0.475771:0.128445:0.084848:0.128445:0.015644:0.008197:0.008890:0.014239:0.006388:0.010660:0.005124:0.003848:0.007466:0.005138:0.013143:0.005138:0.011738:0.012508:0.012950:0.013143:0.006523:0.003848:0.010660:0.012508:0.005138:0.005713:0.012508:0.012950:0.011699:0.003848:0.013143:0.006523:0.012604:0.005792:0.005118:0.012604:0.006042:0.005128:0.008197:0.006388:0.012450:0.012508:0.003848:0.003848:0.005138:0.013143:0.012450:0.006388
tivity. Ipilimumab  is a monoclonal  anti-:@0.084848:0.159864:0.475756:0.159864:0.475756:0.144108:0.084848:0.144108:0.006523:0.003848:0.010660:0.003848:0.006523:0.010314:0.005330:0.012411:0.004349:0.013123:0.003848:0.003848:0.003848:0.018049:0.011699:0.018049:0.013143:0.013123:0.005330:0.007095:0.003848:0.007466:0.012411:0.013143:0.012411:0.018049:0.012604:0.011738:0.012604:0.012450:0.003848:0.012604:0.011738:0.013143:0.003848:0.005330:0.007066:0.013143:0.011738:0.006523:0.003848:0.006388
body that binds to CTLA-4 and inhibits the :@0.084848:0.175528:0.481082:0.175528:0.481082:0.159772:0.084848:0.159772:0.013123:0.012604:0.013181:0.010314:0.005753:0.006523:0.011738:0.013143:0.006523:0.005753:0.013123:0.003848:0.011738:0.013181:0.007466:0.005753:0.006523:0.012604:0.005753:0.015644:0.008197:0.008890:0.014239:0.006388:0.010660:0.005753:0.013143:0.011738:0.013181:0.005753:0.003848:0.011738:0.011738:0.003848:0.013123:0.003848:0.006523:0.007466:0.005767:0.006523:0.011738:0.012508:0.005330
interaction  of  CTLA-4  with  its ligands, :@0.084848:0.191191:0.481086:0.191191:0.481086:0.175435:0.084848:0.175435:0.003848:0.011738:0.006523:0.012508:0.005792:0.013143:0.012450:0.006523:0.003848:0.012604:0.011738:0.005330:0.010678:0.012604:0.006042:0.005330:0.010685:0.015644:0.008197:0.008890:0.014239:0.006388:0.010660:0.005330:0.010683:0.015990:0.003848:0.006523:0.011738:0.005330:0.010689:0.003848:0.006523:0.007466:0.016029:0.003848:0.003848:0.012950:0.013143:0.011738:0.013181:0.007466:0.005330:0.005330
CD80/CD86.  Inhibition of CTLA-4 has :@0.084848:0.206854:0.481106:0.206845:0.481106:0.191089:0.084848:0.191098:0.015644:0.014124:0.010468:0.010468:0.008217:0.015452:0.014124:0.010468:0.010468:0.005330:0.018140:0.015875:0.004156:0.011545:0.011545:0.003656:0.012931:0.003656:0.006331:0.003656:0.012411:0.011545:0.015875:0.012411:0.005850:0.015875:0.015452:0.008005:0.008698:0.014047:0.006196:0.010468:0.015875:0.011545:0.012950:0.007470:0.700821
128:@0.199435:0.201226:0.217856:0.201226:0.217856:0.192040:0.199435:0.192040:0.006103:0.006103:0.006215
been shown to augment T-cell activation :@0.084843:0.222508:0.481100:0.222508:0.481100:0.206752:0.084843:0.206752:0.012931:0.012315:0.012315:0.011545:0.008082:0.007274:0.011545:0.012411:0.015798:0.011545:0.008082:0.006331:0.012411:0.008082:0.012950:0.011507:0.012758:0.017857:0.012315:0.011545:0.006331:0.008082:0.008005:0.006196:0.012257:0.012315:0.003656:0.003656:0.008082:0.012950:0.012257:0.006331:0.003656:0.010468:0.012950:0.006331:0.003656:0.012411:0.011736:0.005330
and proliferation, including the activation :@0.084843:0.238172:0.481075:0.238172:0.481075:0.222416:0.084843:0.222416:0.012950:0.011545:0.012989:0.008236:0.012931:0.005519:0.012411:0.003656:0.003656:0.005850:0.012315:0.005600:0.012950:0.006331:0.003656:0.012411:0.011545:0.005138:0.008236:0.003656:0.011545:0.012257:0.003656:0.011507:0.012989:0.003656:0.011545:0.012758:0.008236:0.006331:0.011545:0.012315:0.008236:0.012950:0.012257:0.006331:0.003656:0.010468:0.012950:0.006331:0.003656:0.012411:0.011734:0.005330
and proliferation of tumour-infiltrating T-ef-:@0.084843:0.253835:0.475785:0.253835:0.475785:0.238079:0.084843:0.238079:0.012950:0.011545:0.012989:0.007249:0.012931:0.005519:0.012411:0.003656:0.003656:0.005850:0.012315:0.005600:0.012950:0.006331:0.003656:0.012411:0.011545:0.007251:0.012411:0.005850:0.007249:0.006331:0.011507:0.017857:0.012411:0.011507:0.005600:0.006196:0.003656:0.011545:0.004589:0.004589:0.003656:0.006331:0.005600:0.012950:0.006331:0.003656:0.011545:0.012758:0.007249:0.008005:0.006196:0.012315:0.005850:0.006388
fector  cells.  Inhibition  of  CTLA-4  signalling :@0.084843:0.269498:0.481090:0.269498:0.481090:0.253742:0.084843:0.253742:0.005850:0.012315:0.012257:0.006331:0.012411:0.005600:0.005330:0.003800:0.012257:0.012315:0.003656:0.003656:0.007274:0.005138:0.005330:0.003800:0.004156:0.011545:0.011545:0.003656:0.012931:0.003656:0.006331:0.003656:0.012411:0.011545:0.005330:0.003800:0.012411:0.005850:0.005330:0.003800:0.015452:0.008005:0.008698:0.014047:0.006196:0.010468:0.005330:0.003800:0.007274:0.003656:0.012758:0.011545:0.012950:0.003656:0.003656:0.003656:0.011545:0.012948:0.005330
can also reduce T-regulatory cell function, :@0.084843:0.285162:0.481073:0.285162:0.481073:0.269406:0.084843:0.269406:0.012257:0.012950:0.011545:0.006254:0.012950:0.003656:0.007274:0.012411:0.006254:0.005521:0.012315:0.012989:0.011507:0.012257:0.012315:0.006254:0.008005:0.006196:0.005519:0.012315:0.012758:0.011507:0.003656:0.012950:0.006331:0.012411:0.005600:0.010122:0.006254:0.012257:0.012315:0.003656:0.003656:0.006254:0.005850:0.011507:0.011545:0.012257:0.006331:0.003656:0.012411:0.011545:0.005326:0.005330
which  may  contribute  to  a  general  in-:@0.084843:0.300825:0.475770:0.300825:0.475770:0.285069:0.084843:0.285069:0.015798:0.011545:0.003656:0.012257:0.011545:0.005330:0.007320:0.017857:0.012950:0.010122:0.005330:0.007318:0.012257:0.012411:0.011545:0.006331:0.005600:0.003656:0.012931:0.011507:0.006331:0.012315:0.005330:0.007318:0.006331:0.012411:0.005330:0.007318:0.012950:0.005330:0.007318:0.012758:0.012315:0.011545:0.012315:0.005600:0.012950:0.003656:0.005330:0.007318:0.003656:0.011545:0.006388
crease in T-cell responsiveness, including :@0.084843:0.316488:0.481054:0.316488:0.481054:0.300732:0.084843:0.300732:0.012257:0.005519:0.012315:0.012950:0.007274:0.012315:0.010987:0.003656:0.011545:0.010987:0.008005:0.006196:0.012257:0.012315:0.003656:0.003656:0.010987:0.005521:0.012315:0.007274:0.012931:0.012411:0.011545:0.007274:0.003656:0.010468:0.012315:0.011545:0.012315:0.007274:0.007274:0.005138:0.010987:0.003656:0.011545:0.012257:0.003656:0.011507:0.012989:0.003656:0.011545:0.012946:0.005330
the anti-tumour immune response.:@0.084843:0.332152:0.397992:0.332152:0.397992:0.316396:0.084843:0.316396:0.006331:0.011545:0.012315:0.005138:0.012950:0.011545:0.006331:0.003656:0.006196:0.006331:0.011507:0.017857:0.012411:0.011507:0.005600:0.005138:0.003656:0.017857:0.017857:0.011507:0.011545:0.012315:0.005138:0.005521:0.012315:0.007274:0.012931:0.012411:0.011545:0.007274:0.012315:0.005330
Ipilimumab  is  indicated for previously :@0.103027:0.347815:0.481075:0.347815:0.481075:0.332059:0.103027:0.332059:0.004349:0.013123:0.003848:0.003848:0.003848:0.018049:0.011699:0.018049:0.013143:0.013123:0.005330:0.007601:0.003848:0.007466:0.005330:0.007593:0.003848:0.011738:0.013181:0.003848:0.012450:0.013143:0.006523:0.012508:0.013181:0.012912:0.006042:0.012604:0.005792:0.012912:0.013123:0.005715:0.012508:0.010660:0.003848:0.012604:0.011699:0.007466:0.003848:0.010314:0.005330
treated unresectable or metastatic mela- :@0.084843:0.363478:0.481081:0.363478:0.481081:0.347722:0.084843:0.347722:0.006523:0.005709:0.012508:0.013143:0.006523:0.012508:0.013181:0.006273:0.011699:0.011738:0.005709:0.012508:0.007466:0.012508:0.012450:0.006523:0.013143:0.013123:0.003848:0.012508:0.006273:0.012604:0.005792:0.006263:0.018049:0.012508:0.006523:0.013143:0.007466:0.006523:0.013143:0.006523:0.003848:0.012450:0.006273:0.018049:0.012508:0.003848:0.013143:0.006388:0.005330
noma.:@0.084843:0.379142:0.145707:0.379142:0.145707:0.363386:0.084843:0.363386:0.011738:0.012604:0.018049:0.013143:0.005330
13:@0.145704:0.373497:0.158134:0.373497:0.158134:0.364311:0.145704:0.364311:0.006215:0.006215
Conjugated MAbs:@0.084848:0.411496:0.273424:0.411496:0.273424:0.393681:0.084848:0.393681:0.016677:0.013683:0.012828:0.005559:0.012828:0.014111:0.014111:0.006414:0.013683:0.014111:0.005987:0.019242:0.015822:0.014111:0.009407
Conjugated MAbs have a different mech-:@0.084848:0.428304:0.475771:0.428304:0.475771:0.412548:0.084848:0.412548:0.015644:0.012604:0.011738:0.003906:0.011699:0.012950:0.013143:0.006523:0.012508:0.013181:0.004797:0.017684:0.014239:0.013123:0.007466:0.004811:0.011738:0.013143:0.010660:0.012508:0.004811:0.013143:0.004811:0.013181:0.003848:0.006104:0.006042:0.012508:0.005709:0.012508:0.011738:0.006523:0.004801:0.018049:0.012508:0.012450:0.011738:0.006388
anism of action to that of the naked MAbs, :@0.084848:0.443967:0.481109:0.443967:0.481109:0.428211:0.084848:0.428211:0.013143:0.011738:0.003848:0.007466:0.018049:0.004156:0.012604:0.006042:0.004156:0.013143:0.012450:0.006523:0.003848:0.012604:0.011738:0.004156:0.006523:0.012604:0.004143:0.006523:0.011738:0.013143:0.006523:0.004145:0.012604:0.006042:0.004147:0.006523:0.011738:0.012508:0.004145:0.011738:0.013143:0.009660:0.012508:0.013181:0.004147:0.017684:0.014239:0.013123:0.007466:0.005330:0.005330
as the interaction between the MAb and :@0.084848:0.459630:0.481098:0.459630:0.481098:0.443874:0.084848:0.443874:0.013143:0.007466:0.006677:0.006523:0.011738:0.012508:0.006677:0.003848:0.011738:0.006523:0.012508:0.005792:0.013143:0.012450:0.006514:0.003848:0.012604:0.011738:0.006677:0.013123:0.012508:0.006523:0.015990:0.012508:0.012508:0.011738:0.006677:0.006523:0.011738:0.012508:0.006677:0.017684:0.014239:0.013123:0.006677:0.013143:0.011738:0.013181:0.005330
the antigen is either to facilitate the deliv-:@0.084848:0.475294:0.475758:0.475294:0.475758:0.459538:0.084848:0.459538:0.006523:0.011738:0.012508:0.005888:0.013143:0.011738:0.006523:0.003848:0.012950:0.012508:0.011738:0.005888:0.003848:0.007466:0.005907:0.012508:0.003848:0.006523:0.011738:0.012508:0.005792:0.005886:0.006523:0.012604:0.005890:0.006042:0.013143:0.012450:0.003848:0.003848:0.003848:0.006523:0.013143:0.006523:0.012508:0.005907:0.006523:0.011738:0.012508:0.005888:0.013181:0.012508:0.003848:0.003848:0.010660:0.006388
ery  of  the  toxin  or  to  specifically  target :@0.084848:0.490957:0.481094:0.490957:0.481094:0.475201:0.084848:0.475201:0.012508:0.005792:0.010314:0.005330:0.004897:0.012604:0.006042:0.005330:0.004895:0.006523:0.011738:0.012508:0.005330:0.004893:0.006523:0.012604:0.009236:0.003848:0.011738:0.005330:0.004895:0.012604:0.005792:0.005330:0.004891:0.006523:0.012604:0.005330:0.004893:0.007466:0.013123:0.012508:0.012450:0.003848:0.004686:0.004686:0.012450:0.013143:0.003848:0.003848:0.010314:0.005330:0.004916:0.006523:0.013143:0.005805:0.012950:0.012508:0.006523:0.005330
cancer cells with radiation therapy.:@0.084848:0.506620:0.414759:0.506620:0.414759:0.490864:0.084848:0.490864:0.012450:0.013143:0.011738:0.012450:0.012508:0.005792:0.005330:0.012450:0.012508:0.003848:0.003848:0.007466:0.005330:0.015990:0.003848:0.006523:0.011738:0.005330:0.005792:0.013143:0.013181:0.003848:0.013143:0.006523:0.003848:0.012604:0.011738:0.005330:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.005330
39:@0.414741:0.500990:0.427171:0.500990:0.427171:0.491804:0.414741:0.491804:0.006215:0.006215
Brentuximab vedotin:@0.084848:0.537372:0.299080:0.537372:0.299080:0.519351:0.084848:0.519351:0.012401:0.006842:0.013683:0.012828:0.006414:0.012828:0.011973:0.005131:0.020098:0.014111:0.014111:0.005987:0.011973:0.013683:0.014111:0.013683:0.006414:0.005131:0.012828
Brentuximab vedotin  is a CD30-directed :@0.084848:0.555649:0.481092:0.555649:0.481092:0.539893:0.084848:0.539893:0.011045:0.005717:0.012508:0.011738:0.006523:0.011699:0.009236:0.003848:0.018049:0.013143:0.013123:0.010295:0.010660:0.012508:0.013181:0.012604:0.006523:0.003848:0.011738:0.005330:0.004955:0.003848:0.007466:0.010295:0.013143:0.010295:0.015644:0.014316:0.010660:0.010660:0.006388:0.013181:0.003848:0.005727:0.012508:0.012450:0.006523:0.012508:0.013181:0.005330
antibody-drug  conjugate  indicated  for :@0.084848:0.571313:0.481096:0.571313:0.481096:0.555557:0.084848:0.555557:0.013143:0.011738:0.006523:0.003848:0.013123:0.012604:0.013181:0.010314:0.006388:0.013181:0.005792:0.011699:0.012950:0.005330:0.009354:0.012450:0.012604:0.011738:0.003906:0.011699:0.012950:0.013143:0.006523:0.012508:0.005330:0.009348:0.003848:0.011738:0.013181:0.003848:0.012450:0.013143:0.006523:0.012508:0.013181:0.005330:0.009361:0.006042:0.012604:0.005792:0.005330
treatment of ::@0.084848:0.586976:0.226013:0.586971:0.226013:0.571215:0.084848:0.571220:0.006523:0.005709:0.012508:0.013143:0.006523:0.018049:0.012508:0.011738:0.006523:0.005330:0.012604:0.006042:0.018635:0.403003
134:@0.202032:0.581352:0.220676:0.581352:0.220676:0.572167:0.202032:0.572167:0.006215:0.006215:0.006215
n :@0.084848:0.600101:0.098177:0.600101:0.098177:0.591661:0.084848:0.591661:0.009762:0.003566
 :@0.115149:0.600101:0.118715:0.600101:0.118715:0.591661:0.115149:0.591661:0.003566
Previously untreated Stage III or IV :@0.115151:0.603220:0.434722:0.603220:0.434722:0.587464:0.115151:0.587464:0.011392:0.005713:0.012508:0.010660:0.003848:0.012604:0.011699:0.007466:0.003848:0.010314:0.005330:0.011699:0.011738:0.006523:0.005709:0.012508:0.013143:0.006523:0.012508:0.013181:0.005330:0.009583:0.006523:0.013143:0.012950:0.012508:0.005330:0.004349:0.004349:0.004349:0.005330:0.012604:0.005792:0.005330:0.004349:0.013508:0.005330
Hodgkin’s lymphoma, in combination :@0.115151:0.618884:0.469269:0.618884:0.469269:0.603128:0.115151:0.603128:0.013143:0.012604:0.013181:0.012950:0.009660:0.003848:0.011738:0.006754:0.007466:0.005330:0.003848:0.010314:0.018049:0.013123:0.011738:0.012604:0.018049:0.013143:0.005330:0.005330:0.003848:0.011738:0.005330:0.012450:0.012604:0.018049:0.013123:0.003848:0.011738:0.013143:0.006523:0.003848:0.012604:0.011738:0.005330
with chemotherapy:@0.115151:0.634547:0.299070:0.634547:0.299070:0.618791:0.115151:0.618791:0.015990:0.003848:0.006523:0.011738:0.005330:0.012450:0.011738:0.012508:0.018049:0.012604:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314
n :@0.084848:0.647672:0.098177:0.647672:0.098177:0.639232:0.084848:0.639232:0.009762:0.003566
 :@0.115149:0.647672:0.118715:0.647672:0.118715:0.639232:0.115149:0.639232:0.003566
Hodgkin’s lymphoma at high risk of :@0.115151:0.650791:0.444674:0.650791:0.444674:0.635035:0.115151:0.635035:0.013143:0.012604:0.013181:0.012950:0.009660:0.003848:0.011738:0.006754:0.007466:0.005330:0.003848:0.010314:0.018049:0.013123:0.011738:0.012604:0.018049:0.013143:0.005330:0.013143:0.006523:0.005330:0.011738:0.003839:0.012950:0.011738:0.005330:0.005778:0.003848:0.007466:0.009660:0.005330:0.012604:0.006042:0.005330
relapse or progression as :@0.115151:0.666455:0.349507:0.666455:0.349507:0.650699:0.115151:0.650699:0.005713:0.012508:0.003848:0.013143:0.013123:0.007466:0.012508:0.005330:0.012604:0.005792:0.005330:0.013123:0.005709:0.012604:0.012950:0.005705:0.012508:0.007466:0.007466:0.003848:0.012604:0.011738:0.005330:0.013143:0.007466:0.005330
post-autologous haematopoietic :@0.554552:0.079503:0.869069:0.079503:0.869069:0.063747:0.554552:0.063747:0.013123:0.012604:0.007466:0.006523:0.006388:0.013143:0.011699:0.006523:0.012604:0.003848:0.012604:0.012950:0.012604:0.011699:0.007466:0.005330:0.011738:0.013143:0.012508:0.018049:0.013143:0.006523:0.012604:0.013123:0.012604:0.003848:0.012508:0.006523:0.003848:0.012450:0.005330
stem-cell transplantation (auto-HSCT) :@0.554552:0.095325:0.906149:0.095325:0.906149:0.079569:0.554552:0.079569:0.007466:0.006523:0.012508:0.018049:0.006388:0.012450:0.012508:0.003848:0.003848:0.005330:0.006523:0.005792:0.013143:0.011738:0.007466:0.013123:0.003848:0.013143:0.011738:0.006523:0.013143:0.006523:0.003848:0.012604:0.011738:0.005330:0.007100:0.013143:0.011699:0.006523:0.012604:0.006388:0.013143:0.009583:0.015644:0.008197:0.007100:0.005330
consolidation:@0.554552:0.111147:0.680147:0.111147:0.680147:0.095391:0.554552:0.095391:0.012450:0.012604:0.011738:0.007466:0.012604:0.003848:0.003848:0.013181:0.013143:0.006523:0.003848:0.012604:0.011738
n :@0.524242:0.124418:0.537570:0.124418:0.537570:0.115977:0.524242:0.115977:0.009762:0.003566
 :@0.554542:0.124418:0.558108:0.124418:0.558108:0.115977:0.554542:0.115977:0.003566
Hodgkin’s lymphoma after failure of :@0.554545:0.127537:0.892850:0.127537:0.892850:0.111781:0.554545:0.111781:0.013143:0.012604:0.013181:0.012950:0.009660:0.003848:0.011738:0.006754:0.007466:0.005330:0.003848:0.010314:0.018049:0.013123:0.011738:0.012604:0.018049:0.013143:0.005330:0.013143:0.006042:0.006523:0.012508:0.005777:0.005330:0.006042:0.013143:0.003848:0.003848:0.011699:0.005715:0.012508:0.005330:0.012604:0.006042:0.005330
auto-HSCT or after failure of at least :@0.554545:0.143941:0.889750:0.143941:0.889750:0.128185:0.554545:0.128185:0.013143:0.011699:0.006523:0.012604:0.006388:0.013143:0.009583:0.015644:0.008197:0.005311:0.012604:0.005792:0.005330:0.013143:0.006042:0.006523:0.012508:0.005792:0.005330:0.006042:0.013143:0.003848:0.003848:0.011699:0.005698:0.012508:0.005330:0.012604:0.006042:0.005330:0.013143:0.006523:0.005330:0.003848:0.012508:0.013143:0.007466:0.006523:0.005330
two prior multi-agent chemotherapy :@0.554545:0.160345:0.899850:0.160345:0.899850:0.144589:0.554545:0.144589:0.006523:0.015990:0.012604:0.005330:0.013123:0.005792:0.003848:0.012604:0.005792:0.005330:0.018049:0.011699:0.003848:0.006523:0.003848:0.006388:0.013143:0.012950:0.012508:0.011738:0.006523:0.005330:0.012450:0.011738:0.012508:0.018049:0.012604:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.005330
regimens in patients who are not :@0.554545:0.176749:0.864309:0.176749:0.864309:0.160993:0.554545:0.160993:0.005713:0.012508:0.012950:0.003848:0.018049:0.012508:0.011738:0.007466:0.005330:0.003848:0.011738:0.005330:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.005330:0.015990:0.011738:0.012604:0.005330:0.013143:0.005698:0.012508:0.005330:0.011738:0.012604:0.006523:0.005330
auto-HSCT candidates:@0.554545:0.193153:0.763979:0.193153:0.763979:0.177398:0.554545:0.177398:0.013143:0.011699:0.006523:0.012604:0.006388:0.013143:0.009583:0.015644:0.008197:0.005330:0.012450:0.013143:0.011738:0.013181:0.003848:0.013181:0.013143:0.006523:0.012508:0.007466
n :@0.524242:0.207028:0.537570:0.207028:0.537570:0.198588:0.524242:0.198588:0.009762:0.003566
 :@0.554542:0.207028:0.558108:0.207028:0.558108:0.198588:0.554542:0.198588:0.003566
Systemic anaplastic large-cell :@0.554545:0.210147:0.837012:0.210147:0.837012:0.194391:0.554545:0.194391:0.009583:0.010314:0.007466:0.006523:0.012508:0.018049:0.003848:0.012450:0.005330:0.013143:0.011738:0.013143:0.013123:0.003848:0.013143:0.007466:0.006523:0.003848:0.012450:0.005330:0.003848:0.013143:0.005819:0.012950:0.012508:0.006388:0.012450:0.012508:0.003848:0.003848:0.005330
lymphoma after failure of at least one :@0.554545:0.226552:0.912180:0.226552:0.912180:0.210796:0.554545:0.210796:0.003848:0.010314:0.018049:0.013123:0.011738:0.012604:0.018049:0.013143:0.005330:0.013143:0.006042:0.006523:0.012508:0.005792:0.005330:0.006042:0.013143:0.003848:0.003848:0.011699:0.005711:0.012508:0.005330:0.012604:0.006042:0.005330:0.013143:0.006523:0.005330:0.003848:0.012508:0.013143:0.007466:0.006523:0.005330:0.012604:0.011738:0.012508:0.005330
prior multi-agent chemotherapy :@0.554545:0.242956:0.859402:0.242956:0.859402:0.227200:0.554545:0.227200:0.013123:0.005792:0.003848:0.012604:0.005792:0.005330:0.018049:0.011699:0.003848:0.006523:0.003848:0.006388:0.013143:0.012950:0.012508:0.011738:0.006523:0.005330:0.012450:0.011738:0.012508:0.018049:0.012604:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.005330
regimen:@0.554545:0.259360:0.631859:0.259360:0.631859:0.243604:0.554545:0.243604:0.005713:0.012508:0.012950:0.003848:0.018049:0.012508:0.011738
n :@0.524242:0.273234:0.537570:0.273234:0.537570:0.264794:0.524242:0.264794:0.009762:0.003566
 :@0.554542:0.273234:0.558108:0.273234:0.558108:0.264794:0.554542:0.264794:0.003566
Primary cutaneous anaplastic large-:@0.554545:0.276353:0.891766:0.276353:0.891766:0.260598:0.554545:0.260598:0.011392:0.005792:0.003848:0.018049:0.013143:0.005792:0.010314:0.005330:0.012450:0.011699:0.006523:0.013143:0.011738:0.012508:0.012604:0.011699:0.007466:0.005330:0.013143:0.011738:0.013143:0.013123:0.003848:0.013143:0.007466:0.006523:0.003848:0.012450:0.005330:0.003848:0.013143:0.005809:0.012950:0.012508:0.006388
cell lymphoma or CD30-expressing :@0.554545:0.292758:0.882012:0.292758:0.882012:0.277002:0.554545:0.277002:0.012450:0.012508:0.003848:0.003848:0.005330:0.003848:0.010314:0.018049:0.013123:0.011738:0.012604:0.018049:0.013143:0.005330:0.012604:0.005792:0.005330:0.015644:0.014316:0.010660:0.010660:0.006388:0.012508:0.009236:0.013123:0.005715:0.012508:0.007466:0.007466:0.003848:0.011738:0.012950:0.005330
mycosis fungoides (MF) in patients :@0.554545:0.309162:0.877105:0.309162:0.877105:0.293406:0.554545:0.293406:0.018049:0.010314:0.012450:0.012604:0.007466:0.003848:0.007466:0.005330:0.006042:0.011699:0.011738:0.012950:0.012604:0.003848:0.013181:0.012508:0.007466:0.005330:0.007100:0.017684:0.009333:0.007100:0.005330:0.003848:0.011738:0.005330:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.005330
who have received prior systemic :@0.554545:0.325566:0.872726:0.325566:0.872726:0.309810:0.554545:0.309810:0.015990:0.011738:0.012604:0.005330:0.011738:0.013143:0.010660:0.012508:0.005330:0.005703:0.012508:0.012450:0.012508:0.003848:0.010660:0.012508:0.013181:0.005330:0.013123:0.005792:0.003848:0.012604:0.005792:0.005330:0.007466:0.010314:0.007466:0.006523:0.012508:0.018049:0.003848:0.012450:0.005330
therapy:@0.554545:0.341970:0.627685:0.341970:0.627685:0.326214:0.554545:0.326214:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314
Radiolabelled MAbs :@0.524242:0.370318:0.739329:0.370318:0.739329:0.352297:0.524242:0.352297:0.012401:0.014111:0.014111:0.005131:0.013683:0.005131:0.014111:0.014111:0.013683:0.005131:0.005131:0.013683:0.014111:0.005987:0.019242:0.015822:0.014111:0.009407:0.005987
The radiolabelled antibody, ibritumomab :@0.524242:0.389339:0.920487:0.389339:0.920487:0.373583:0.524242:0.373583:0.008197:0.011738:0.012508:0.008084:0.005792:0.013143:0.013181:0.003848:0.012604:0.003848:0.013143:0.013123:0.012508:0.003848:0.003862:0.012508:0.013181:0.008091:0.013143:0.011738:0.006523:0.003848:0.013123:0.012604:0.013181:0.010314:0.005330:0.008101:0.003848:0.013123:0.005792:0.003848:0.006523:0.011699:0.018049:0.012604:0.018049:0.013143:0.013123:0.005330
tiuxetan, is a monoclonal mouse antibody :@0.524242:0.405743:0.920476:0.405743:0.920476:0.389987:0.524242:0.389987:0.006523:0.003848:0.011699:0.009236:0.012508:0.006523:0.013143:0.011738:0.005330:0.005292:0.003848:0.007466:0.005305:0.013143:0.005292:0.018049:0.012604:0.011738:0.012604:0.012450:0.003848:0.012604:0.011738:0.013143:0.003848:0.005292:0.018049:0.012604:0.011699:0.007466:0.012508:0.005292:0.013143:0.011738:0.006523:0.003848:0.013123:0.012604:0.013181:0.010314:0.005330
conjugated with the chelator tiuxetan to :@0.524242:0.422147:0.920483:0.422147:0.920483:0.406391:0.524242:0.406391:0.012450:0.012604:0.011738:0.003906:0.011699:0.012950:0.013143:0.006523:0.012508:0.013181:0.007676:0.015990:0.003848:0.006523:0.011738:0.007682:0.006523:0.011738:0.012508:0.007678:0.012450:0.011738:0.012508:0.003848:0.013143:0.006523:0.012604:0.005792:0.007676:0.006523:0.003848:0.011699:0.009236:0.012508:0.006523:0.013143:0.011738:0.007680:0.006523:0.012604:0.005330
which a radio-isotope indium-111 is add-:@0.524242:0.438551:0.915147:0.438551:0.915147:0.422795:0.524242:0.422795:0.015990:0.011738:0.003848:0.012450:0.011738:0.008082:0.013143:0.008082:0.005792:0.013143:0.013181:0.003848:0.012604:0.006388:0.003848:0.007466:0.012604:0.006523:0.012604:0.013123:0.012508:0.008082:0.003848:0.011738:0.013181:0.003848:0.011699:0.018049:0.006388:0.010660:0.010660:0.010660:0.008097:0.003848:0.007466:0.008082:0.013143:0.013181:0.013181:0.006388
ed.  The monoclonal antibody section of :@0.524242:0.454955:0.920470:0.454957:0.920470:0.439201:0.524242:0.439199:0.012508:0.013181:0.005330:0.012431:0.006427:0.008197:0.011738:0.012508:0.006427:0.018049:0.012604:0.011738:0.012592:0.012450:0.003848:0.012604:0.011738:0.013143:0.003848:0.006427:0.013143:0.011738:0.006523:0.003848:0.013123:0.012604:0.013181:0.010314:0.006427:0.007466:0.012508:0.012450:0.006523:0.003848:0.012604:0.011738:0.006427:0.012604:0.006042:-0.099433
48:@0.555257:0.449338:0.567687:0.449338:0.567687:0.440152:0.555257:0.440152:0.006215:0.006215
ibritumomab tiuxetan is capable of bind-:@0.524242:0.471361:0.915140:0.471361:0.915140:0.455605:0.524242:0.455605:0.003848:0.013123:0.005792:0.003848:0.006523:0.011699:0.018049:0.012604:0.018049:0.013143:0.013123:0.007254:0.006523:0.003848:0.011699:0.009236:0.012508:0.006523:0.013143:0.011738:0.007254:0.003848:0.007466:0.007266:0.012450:0.013143:0.013123:0.013143:0.013123:0.003848:0.012508:0.007270:0.012604:0.006042:0.007254:0.013123:0.003848:0.011738:0.013181:0.006388
ing to B-lymphocytes; it therefore delivers :@0.524242:0.487765:0.920462:0.487765:0.920462:0.472009:0.524242:0.472009:0.003848:0.011738:0.012950:0.007100:0.006523:0.012604:0.007100:0.011045:0.006388:0.003848:0.010314:0.018049:0.013123:0.011738:0.012604:0.012450:0.010314:0.006523:0.012508:0.007466:0.005330:0.007100:0.003848:0.006523:0.007100:0.006523:0.011738:0.012508:0.005705:0.012508:0.006042:0.012604:0.005705:0.012508:0.007100:0.013181:0.012508:0.003848:0.003848:0.010660:0.012508:0.005792:0.007466:0.005330
a dose of radiation to the cell and the an-:@0.524242:0.504169:0.915161:0.504169:0.915161:0.488413:0.524242:0.488413:0.013143:0.005215:0.013181:0.012604:0.007466:0.012508:0.005215:0.012604:0.006042:0.005215:0.005792:0.013143:0.013181:0.003848:0.013143:0.006523:0.003848:0.012604:0.011738:0.005215:0.006523:0.012604:0.005205:0.006523:0.011738:0.012508:0.005205:0.012450:0.012508:0.003848:0.003848:0.005215:0.013143:0.011738:0.013181:0.005215:0.006523:0.011738:0.012508:0.005205:0.013143:0.011738:0.006388
tibody binds  to its neighbouring cells  as :@0.524242:0.520573:0.920460:0.520573:0.920460:0.504817:0.524242:0.504817:0.006523:0.003848:0.013123:0.012604:0.013181:0.010314:0.009948:0.013123:0.003848:0.011738:0.013181:0.007466:0.005330:0.004632:0.006523:0.012604:0.009948:0.003848:0.006523:0.007466:0.009948:0.011738:0.012508:0.003848:0.012950:0.011738:0.013123:0.012604:0.011690:0.005792:0.003848:0.011738:0.012950:0.009948:0.012450:0.012508:0.003848:0.003848:0.007466:0.005330:0.004632:0.013143:0.007466:0.005330
well.:@0.524242:0.536978:0.565767:0.536978:0.565767:0.521222:0.524242:0.521222:0.015990:0.012508:0.003848:0.003848:0.005330
48:@0.565771:0.531360:0.578201:0.531360:0.578201:0.522175:0.565771:0.522175:0.006215:0.006215
Ibritumomab tiuxetan is  deliberately :@0.542424:0.553384:0.920472:0.553384:0.920472:0.537628:0.542424:0.537628:0.004349:0.013123:0.005792:0.003848:0.006523:0.011699:0.018049:0.012604:0.018049:0.013143:0.013123:0.018242:0.006523:0.003848:0.011699:0.009236:0.012508:0.006523:0.013143:0.011738:0.018242:0.003848:0.007466:0.005330:0.012923:0.013181:0.012508:0.003848:0.003848:0.013123:0.012508:0.005792:0.013143:0.006523:0.012508:0.003848:0.010314:0.005330
kept as a monoclonal mouse antibody to :@0.524240:0.569788:0.920508:0.569788:0.920508:0.554032:0.524240:0.554032:0.009660:0.012508:0.013123:0.006523:0.006138:0.013143:0.007466:0.006138:0.013143:0.006138:0.018049:0.012604:0.011738:0.012594:0.012450:0.003848:0.012604:0.011738:0.013143:0.003848:0.006138:0.018049:0.012604:0.011699:0.007466:0.012508:0.006138:0.013143:0.011738:0.006523:0.003848:0.013123:0.012604:0.013181:0.010314:0.006138:0.006523:0.012604:0.005330
ensure rapid elimination from the body.  :@0.524240:0.586192:0.920481:0.586193:0.920481:0.570437:0.524240:0.570436:0.012508:0.011738:0.007466:0.011699:0.005709:0.012508:0.007666:0.005792:0.013143:0.013123:0.003848:0.013181:0.007678:0.012508:0.003848:0.003848:0.018049:0.003848:0.011738:0.013143:0.006523:0.003848:0.012604:0.011738:0.007678:0.006042:0.005711:0.012604:0.018049:0.007664:0.006523:0.011738:0.012508:0.007660:0.013123:0.012604:0.013181:0.010314:0.005330:0.012426:-0.290333
48:@0.902716:0.580574:0.915146:0.580574:0.915146:0.571389:0.902716:0.571389:0.006215:0.006215
The main side effect of ibritumomab tiux-:@0.524241:0.602597:0.915154:0.602597:0.915154:0.586841:0.524241:0.586841:0.008197:0.011738:0.012508:0.007062:0.018049:0.013143:0.003848:0.011738:0.007072:0.007466:0.003848:0.013181:0.012508:0.007081:0.012508:0.006096:0.006042:0.012508:0.012450:0.006523:0.007066:0.012604:0.006042:0.007066:0.003848:0.013123:0.005792:0.003848:0.006523:0.011699:0.018049:0.012604:0.018049:0.013143:0.013123:0.007072:0.006523:0.003848:0.011699:0.009236:0.006388
etan is myelosuppression.:@0.524241:0.619001:0.759543:0.619001:0.759543:0.603246:0.524241:0.603246:0.012508:0.006523:0.013143:0.011738:0.005330:0.003848:0.007466:0.005330:0.018049:0.010314:0.012508:0.003848:0.012604:0.007466:0.011699:0.013123:0.013123:0.005721:0.012508:0.007466:0.007466:0.003848:0.012604:0.011738:0.005330
48:@0.759539:0.613383:0.771969:0.613383:0.771969:0.604198:0.759539:0.604198:0.006215:0.006215
Contra-indications, special  precautions :@0.542424:0.634819:0.920491:0.634819:0.920491:0.619063:0.542424:0.619063:0.015644:0.012604:0.011738:0.006523:0.005792:0.013143:0.006388:0.003848:0.011738:0.013181:0.003848:0.012450:0.013143:0.006523:0.003848:0.012604:0.011738:0.007466:0.005330:0.008986:0.007466:0.013123:0.012508:0.012450:0.003848:0.013143:0.003848:0.005330:0.003670:0.013123:0.005713:0.012508:0.012450:0.013143:0.011699:0.006523:0.003848:0.012604:0.011738:0.007466:0.005330
and drug interactions: See :@0.524240:0.650641:0.778586:0.650641:0.778586:0.634885:0.524240:0.634885:0.013143:0.011738:0.013181:0.006408:0.013181:0.005792:0.011699:0.012950:0.006408:0.003848:0.011738:0.006523:0.012508:0.005792:0.013143:0.012450:0.006523:0.003848:0.012604:0.011738:0.007466:0.005330:0.006408:0.009583:0.012508:0.012508:0.005330
MIMS Monthly, :@0.779663:0.650641:0.920479:0.650641:0.920479:0.634885:0.779663:0.634885:0.017684:0.004349:0.017684:0.009583:0.006408:0.017684:0.012604:0.011738:0.006523:0.011738:0.003848:0.010314:0.005330:0.005330
MDR:@0.524240:0.666463:0.567920:0.666463:0.567920:0.650707:0.524240:0.650707:0.017684:0.014316:0.011680
 or manufacturer’s product literature.:@0.567920:0.666463:0.913048:0.666463:0.913048:0.650707:0.567920:0.650707:0.005330:0.012604:0.005792:0.005330:0.018049:0.013143:0.011738:0.011699:0.006042:0.013143:0.012450:0.006523:0.011699:0.005694:0.012508:0.005792:0.006754:0.007466:0.005330:0.013123:0.005711:0.012604:0.013181:0.011699:0.012450:0.006523:0.005330:0.003848:0.003848:0.006523:0.012508:0.005792:0.013143:0.006523:0.011699:0.005698:0.012508:0.005330
DRUG-CLASS OVERVIEW:@0.084848:0.038601:0.357590:0.038601:0.357590:0.019343:0.084848:0.019343:0.017498:0.014276:0.015405:0.020508:0.007808:0.019121:0.010866:0.017404:0.011712:0.011712:0.006515:0.020438:0.016510:0.012606:0.013356:0.016510:0.005315:0.012606:0.022578